Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors;Monitorering af tumornekrosefaktor alfa-hæmmeres biotilgængelighed, farmakokinetik og immunogenicitet

Ugeskrift for Laeger

Volumn 172, Issue 1, 2010, Pages

  Steenholdt, Casper ^a   Ainsworth, Mark ^a   Thomsen, Ole Østergaard ^a   Brynskov, Jorn ^a   Bendtzen, Klaus ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIINFLAMMATORY AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOAVAILABILITY; BLOOD; CROHN DISEASE; DRUG ANTAGONISM; DRUG MONITORING; ENTERITIS; HUMAN; IMMUNOLOGY; PERSONALIZED MEDICINE; TIME; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; CROHN DISEASE; DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; INFLAMMATORY BOWEL DISEASES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950480144     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. European Medicines Agency. European public assessment report (EPAR) for Remicade. www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H-240-PI-en.pdf (6. november 2008).
2. Clark M, Colombel JF, Feagan BC et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterol 2007;133:312-39.
3. www.medstat.dk (6. november 2008).
4. European Medicines Agency. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. www.emea.europa.eu/pdfs/human/ewp/8924904enfin.pdf (24. januar 2007).
5. Bendtzen K. Immunogenicity of anti-TNF antibodies. I: van de Weert M, Møller EH, eds. Biotechnology: Pharmaceutical Aspects Vol. VIII. Immunogenicity of biopharmaceuticals. New York: Springer, 2008;189-203.
6. Bendtzen K, Geborek P, Svenson M et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor Infliximab. Arthritis Rheum 2006;54:3782-9.
7. Bendtzen K. Problemer ved klinisk brug af rekombinante proteiner. Ugeskr Læger 2003;165:4625.
8. Bendtzen K, Ainsworth MA, Steenholdt C et al. Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774-81.
9. Svenson M, Geborek P, Saxne T et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals - assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007;46:1828-34.
10. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8.
11. West RL, Zelinkova Z, Wolbink GJ et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008;28:1122-6